India rejects BMS' atazanavir bisulphate patent but Novartis' claims still alive
This article was originally published in Scrip
Executive Summary
India has rejected Bristol Myers Squibb's patent application for the bisulphate version of the AIDS drug atazanavir, but Novartis continues to pursue separate rights for atazanavir under a divisional application, the company said.